KalVista Pharmaceuticals (KALV) & Ocera Therapeutics (OCRX) Head to Head Analysis

KalVista Pharmaceuticals (NASDAQ: KALV) and Ocera Therapeutics (NASDAQ:OCRX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

Earnings & Valuation

This table compares KalVista Pharmaceuticals and Ocera Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
KalVista Pharmaceuticals $1.50 million 85.84 -$18.60 million N/A N/A
Ocera Therapeutics $610,000.00 74.31 -$26.89 million ($1.05) -1.63

KalVista Pharmaceuticals has higher revenue and earnings than Ocera Therapeutics.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for KalVista Pharmaceuticals and Ocera Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
KalVista Pharmaceuticals 0 0 1 0 3.00
Ocera Therapeutics 0 3 1 0 2.25

KalVista Pharmaceuticals presently has a consensus price target of $27.00, suggesting a potential upside of 103.62%. Ocera Therapeutics has a consensus price target of $1.92, suggesting a potential upside of 12.09%. Given KalVista Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts clearly believe KalVista Pharmaceuticals is more favorable than Ocera Therapeutics.

Insider & Institutional Ownership

75.6% of KalVista Pharmaceuticals shares are owned by institutional investors. Comparatively, 20.2% of Ocera Therapeutics shares are owned by institutional investors. 49.1% of KalVista Pharmaceuticals shares are owned by insiders. Comparatively, 7.2% of Ocera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares KalVista Pharmaceuticals and Ocera Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
KalVista Pharmaceuticals -4,191.47% -60.42% -55.11%
Ocera Therapeutics N/A -175.02% -89.76%

Risk and Volatility

KalVista Pharmaceuticals has a beta of 3.05, suggesting that its stock price is 205% more volatile than the S&P 500. Comparatively, Ocera Therapeutics has a beta of 2.31, suggesting that its stock price is 131% more volatile than the S&P 500.

Summary

KalVista Pharmaceuticals beats Ocera Therapeutics on 10 of the 11 factors compared between the two stocks.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company’s HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.

About Ocera Therapeutics

Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.

Receive News & Ratings for KalVista Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply